Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 11/20 | 0.43 |
| ▸ | EP300 | Q09472 | 5/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593589 | 0.83 | KAT2B (0.42) | KAT2BCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5593596 | 0.75 | RECQL (0.51) | KAT2BEP300 | |
| SCHEMBL9132193 | 0.72 | KAT2B (0.63) | KAT2BEP300PIN1IDO1 | |
| SCHEMBL14564368 | 0.71 | RORB (0.42) | NTRK1 | |
| SCHEMBL22657 | 0.63 | KAT2B (1.00) | KAT2BEP300PIN1IDO1 | |
| SCHEMBL9130886 | 0.63 | KAT2B (0.73) | KAT2BEP300PIN1IDO1 | |
| SCHEMBL9727832 | 0.63 | CYP2A6 (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5593553 | 0.62 | RECQL (0.50) | KAT2B | |
| SCHEMBL3110788 | 0.62 | KAT2B (0.56) | KAT2BEP300PIN1CYP1A2 | |
| SCHEMBL2091654 | 0.61 | KDM1A (0.48) | IDO1JAK2CYP3A4ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293374-A1 | Substituted isothiazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293374-A1 | Substituted isothiazolones | LTB4R2, PTGES2, CYSLTR2 | KAT2B 1199/4885EP300 2114/4885PIN1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.